BC Week In Review | Oct 17, 2016
Clinical News

QGC001: Phase IIa data

Top-line data from the double-blind, placebo-controlled, crossover, French Phase IIa 2QG1 trial in 34 patients with moderate grade I or II hypertension showed that oral QGC001 led to “positive signals on several endpoints.” Quantum declined...
BC Week In Review | Jul 18, 2016
Clinical News

QGC101: Phase IIa started

Quantum Genomics began the double-blind, placebo-controlled, European Phase IIa QUID HF trial to evaluate 50-500 mg oral QGC101 twice daily for 28 days in about 75 CHF patients with altered cardiac ejection fraction. Quantum Genomics...
BC Week In Review | Oct 19, 2015
Clinical News

QGC001: Phase IIa ongoing

Quantum Genomics said an independent monitoring board recommended continuation of a double-blind, placebo-controlled, crossover, French Phase IIa trial evaluating 500 mg oral QGC001 twice daily. Early last month, the company said the trial had enrolled...
BC Innovations | Mar 5, 2015
Distillery Therapeutics

Therapeutics: S. aureus M42 family glutamyl aminopeptidase (PepA1)

Infectious disease INDICATION: Bacterial infection Cell culture studies suggest a cyclic heptapseudopeptide derived from the Staphylococcus aureus toxin PepA1 could help treat both Gram-negative and Gram-positive bacterial infections without the hematological toxicity of the parent...
BC Extra | Feb 18, 2015
Financial News

Quantum Genomics raises EUR 33.2M

Quantum Genomics Corp. (Euronext:ALQGC) raised EUR 33.2 million ($37.9 million) through the sale of 5.3 million shares at EUR 6.30 in a public offering and private placement on the Alternext market of Euronext Paris underwritten...
Items per page:
1 - 5 of 5